Let's stop trying to cure cancer, says cancer professor

mahjongking said:
thats why when you hear the person relapse, half the time means game over.....
Click to expand...
From my observation, depending on the type of cancer and also preferably with a surgery to remove the tumor, if you manage to pull through the first 3 years, you should be able to survive until the 5th year. If you still pull through the 5th year, then the 8th year is a good chance. After that, it'll all depend on your fate.

The greatest fear is that the surgery did not totally eliminate the cancer cells but some would have contaminated the nearby lymph cells during the surgery. Thereafter, those few surviving cancer cells will travel with the blood stream and subsequently metastasize at other location in the later stage.
 
Last edited:
myfoot123 said:
Cancer is reversible thru fasting. Let the cancer cell go hungry and then they eat each other until no more is left. They thrive on sugar.
Click to expand...
Avoiding sugary foods is a very good starting point. Cancer cells just love sugar and yes, they thrive on it.
 

China-Singapore team’s nanovaccine suppresses cancer recurrence and spread in animal tests​

Preliminary results hold promise of personalised treatments, but clinical trials are still a long way off, scientists say
Researchers from the Chinese Academy of Sciences’ Institute of Nanoscience and the National University of Singapore are working on a cancer treatment that uses nanotechnology to attack tumours. Photo: Shutterstock

Zhang Tong in Beijing
Published: 3:55pm, 21 Jul 2025


A joint China-Singapore research team is using nanoparticle technology to create a cancervaccine that has produced promising results in animal tests – reducing the regrowth and spread of tumours up to seven times more effectively than existing treatments.


The nanovaccine attacks not only regular cancerous cells but also cancer stem cells (CSCs), which can lie dormant within tumours during treatment, only awakening when conditions are more favourable to the disease.


The bioinspired approach developed by the researchers, led by Yang Yanlian from the National Centre for Nanoscience and Technology and Chen Xiaoyuan from the National University of Singapore, has potential for personalised cancer vaccines.


The researchers detailed their findings in a paper published last month by the peer-reviewed Nature Nanotechnology.
 
Post-surgical recurrence and metastasis of cancers are mainly driven by CSCs, which are highly resistant to conventional therapies. Some studies have even suggested that traditional treatments like radiotherapy may inadvertently promote their spread.


The body’s normal stem cells work continuously, whether generating blood or helping to renew the gut’s lining every three to five days. But their unique self-renewal and unlimited proliferation qualities are also harboured by CSCs within tumours.


icon-video.svg
Biological robots made from human cells show promise for use in medical treatment

In an interview with China Science Daily published on July 2, Yang likened CSCs to a tumour’s “special forces” because of their ability to survive treatment by going into a dormant period, before reawakening and resuming activity
 
“CSCs possess self-renewal and differentiation capabilities – they not only proliferate into tumour cells but also generate heterogeneous cancer cell populations, accelerating recurrence and metastasis,” she said.


“Current targeted chemotherapy and antibody therapies effectively kill ordinary tumour cells with minimal harm to the body. However, they struggle against CSCs. Even if just 1-5 per cent of CSCs remain, they can cause relapse. Only by completely eradicating CSCs can we suppress recurrence and metastasis.”


According to the paper, the researchers discovered in 2021 that the immune system could simultaneously attack tumour cells and CSCs, but the exact activation mechanism remained unclear.

A major hurdle was that vaccine effectiveness was often weakened because dendritic cells – the immune system’s “scouts” that present tumour antigens to T-cells – contained proteases, the researchers said.


These protein-degrading enzymes, found in the cellular waste processors called lysosomes, break down vaccine proteins, impairing immune activation. The team combined expertise in nanotechnology and chemistry to overcome this challenge.


The researchers said the nanovaccine had three key features that made it effective, starting with an outer shell of tiny, bubblelike particles taken from tumorous cell membranes.
 
k1976 said:

China-Singapore team’s nanovaccine suppresses cancer recurrence and spread in animal tests​

Preliminary results hold promise of personalised treatments, but clinical trials are still a long way off, scientists say
Researchers from the Chinese Academy of Sciences’ Institute of Nanoscience and the National University of Singapore are working on a cancer treatment that uses nanotechnology to attack tumours. Photo: Shutterstock

Zhang Tong in Beijing
Published: 3:55pm, 21 Jul 2025


A joint China-Singapore research team is using nanoparticle technology to create a cancervaccine that has produced promising results in animal tests – reducing the regrowth and spread of tumours up to seven times more effectively than existing treatments.


The nanovaccine attacks not only regular cancerous cells but also cancer stem cells (CSCs), which can lie dormant within tumours during treatment, only awakening when conditions are more favourable to the disease.


The bioinspired approach developed by the researchers, led by Yang Yanlian from the National Centre for Nanoscience and Technology and Chen Xiaoyuan from the National University of Singapore, has potential for personalised cancer vaccines.


The researchers detailed their findings in a paper published last month by the peer-reviewed Nature Nanotechnology.
Click to expand...
china?

need some advice who ish SURE notch happy about this lolololololol...
 

Pfizer Enters into Exclusive Licensing Agreement with 3SBio​

Monday, May 19, 2025 - 08:00pm
View pdfcopyCopy to clipboardOpen in tab
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial efficacy and safety data in a promising class of cancer medicines. 3SBio plans to initiate the first Phase 3 study in China in 2025.

Under the terms of the agreement, 3SBio and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd. will grant Pfizer an exclusive global license to develop, manufacture and commercialize SSGJ-707 worldwide, excluding China. The agreement also provides Pfizer the option of commercialization rights in China. 3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion as well as tiered double-digit royalties on sales of SSGJ-707, if approved.

The transaction is expected to close in the third quarter subject to fulfillment of customary closing conditions, including receipt of required regulatory approvals and 3SBio shareholder approval. Upon close, Pfizer will make a $100 million equity investment in 3SBio subject to an agreed upon securities subscription agreement between the parties. Pfizer plans to manufacture drug substance for SSGJ-707 in Sanford, North Carolina, and drug product in McPherson, Kansas.
 

Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival​

marketwatch.dad5abb.png

Provided by Dow Jones May 20, 2025 at 11:13:00 PM
By Tomi Kilgore

Pfizer's licensing deal with China's 3Sbio for PD-1/VEGF antibody has an upfront payment more than double what Merck paid last year for its deal with China's LaNova

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company.

The company (PFE) announced late Monday a license agreement with China-based 3SBio Inc. HK:1530 to develop, make and sell an antibody - SSGJ-707 - that targets PD-1 and VEGF, which suppresses the immune system from fighting cancer cells.

And although Pfizer's deal is with a China-based company, Pfizer said it plans to manufacture drug substance for SSGJ-7807 in Sanford, N.C., and make drug product in McPherson, Kan.

As Evercore ISI analyst Cory Kasimov said, securing U.S. manufacturing was "an obvious response" to the current tariff environment.

The financial terms of the deal include a $1.25 billion upfront payment, and payments of up to $4.8 billion if certain development, regulatory and sales milestones are reached. After the deal closes, which is expected to occur in the third quarter, Pfizer will make a $100 million equity investment in 3Sbio.

To put Pfizer's deal in perspective, rival Merck & Co. Inc. (MRK) had announced in November 2024 a licensing deal with Shanghai-based LaNova Medicines Ltd. for PD-1/VEGF antibody LM-299, in which it paid $588 million upfront, and could make up to $2.7 billion in milestone payments. Merck's current cancer treatment, Keytruda, which can be used in combination with chemotherapy, had $7.8 billion in sales in 2024.
 
myfoot123 said:
Cancer is reversible thru fasting. Let the cancer cell go hungry and then they eat each other until no more is left. They thrive on sugar.
Click to expand...
But now they say if fasting, the cells will feed the cancer cells leh...
 
Aspirin? I thought its ivermectin or fenbendazole.
Nowadays got AI so no problem. No need to consult doctors. Just use chatgpt, deep seek, openAI or Grok
 
syed putra said:
Aspirin? I thought its ivermectin or fenbendazole.
Nowadays got AI so no problem. No need to consult doctors. Just use chatgpt, deep seek, openAI or Grok
Click to expand...
Horse medicine work on only certain type of cancer
 
syed putra said:
Aspirin? I thought its ivermectin or fenbendazole.
Nowadays got AI so no problem. No need to consult doctors. Just use chatgpt, deep seek, openAI or Grok
Click to expand...
Many sheeple already being indoctrinated since young. Sick must see a doctor.

In Singapore, the dependence on medical doctors are extremely huge. Just see the number of hospitals will tell you the answer.

If you have been following the mainstream media, the mainstream media has been brainwashing the sheeple to trust the local medical system again after Covid-19
 
Last edited:
Leongsam said:
I actually know someone who was cured of cancer via diet, exercise and meditation. She had surgery to remove the tumor but no radio or chemo. 10 years later and still going strong.
Click to expand...

 
You must log in or register to reply here.

Similar threads

Nanodick
A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first.
Replies
1
Views
682
tobelightlight
T
Nanodick
New vaccine to treat 15 types of cancer now available on NHS
Replies
7
Views
1K
tobelightlight
T
Rogue Trader
[Not halal] Chinese cancer researchers turn 90% of tumours into "pork" so immune system can kill it
Replies
4
Views
507
worcer
W
Nanodick
This Common Symptom Lasting More Than 3 Weeks May Signal Cancer Risk
Replies
0
Views
327
Nanodick
Nanodick
Leongsam
Cancer - the best way to die!
Replies
10
Views
693
Leongsam
Leongsam
Back
Top